论文部分内容阅读
小剂量化疗的基本原理用小剂量化疗医治骨髓增生异常综合征(MDS),主要根据两种考虑:第一,MDS患者年龄较大,不能很好耐受强烈诱导化疗,大约50%MDS病人用强烈治疗诱导失败的原因是由于骨髓增生抑制引起的感染或出血。但是大家认为,若减少细胞毒药物的剂量即可增进其实用价值,它可以停止或至少延迟MDS的进展。其次,用小剂量化疗医治MDS系依据在体外某些药物如Ara-C、阿克拉霉素、5-氮杂胞苷(5-azacytidine)、6-硫鸟嘌呤等,具有促进髓系白血病细胞分化成熟的能力。
Basic principles of low-dose chemotherapy Treatment of myelodysplastic syndrome (MDS) with low-dose chemotherapy is based on two considerations: first, patients with MDS are older and do not tolerate intensive induction chemotherapy and about 50% of patients with MDS Intense treatment induces failure due to infection or bleeding due to inhibition of myeloproliferation. However, it is thought that halting or at least slowing the progression of MDS may be of value if the dose of cytotoxic drug is reduced. Second, the treatment of MDS with low-dose chemotherapy is based on certain drugs in vitro such as Ara-C, aclacinomycin, 5-azacytidine, 6-thioguanine and so on, with the promotion of myeloid leukemia cells The ability to differentiate and mature.